Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Data from three terminally ill cardiogenic shock patients showcase potential of procizumab to safely reverse shock within 48 hours and provide promising first-in-human evidence on the translatability ...

If you have $1,000 to invest right now, you may be wondering where to get started. You could buy stocks that are flying high ...

A new class of South Korean immunotherapy drugs is raising hopes for a breakthrough in the treatment of a rare blood cancer ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

Scientists have discovered that a locally developed cancer drug, PRL3-zumab, may offer a groundbreaking treatment for two ...

In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in ...

Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia ...

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

Daré Bioscience shares rallied after the biopharmaceutical company released positive interim safety and efficacy results from the Phase 3 clinical trial of its contraceptive drug. Shares climbed 86% ...